维普期刊资源整合服务平台（V6.5）

203篇 您的检索式：作者名="SALTZ LB"

选中清除导出查看参考文献查看引证文献引用追踪共11页首页上一页第1页下一页末页 /11 跳转

	题名	作者	年代	出处	被引量
1	Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:a randomized phase Ⅲ study显示文摘	Saltz LB Clarke S Díaz-Rubio E		0，，12：	2
2	Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer显示文摘	Saltz LB Cox JV Blanke C	2000	N Engl J Med2000，343，13：	1
3	lrinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer显示文摘	Saltz LB Cox JV Blanke C	2000	NEngl JMed2000，343，13：	1
4	Bevacizumab in combination with oxaliplatin-based chemotherapy as frist-line therapy in metastatic colorectal cancer:a randomized phase Ⅲ study显示文摘	Saltz LB Clarke S Diza-Rubio E		0，，20：	1
5	Phase lI trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor显示文摘	Saltz LB Meropol N J Loehrer PJ Sr	2004	J Clin Oncol2004，22，7：	1
6	Bevacizunmb in combination with oxaliplatin-based chemotherapy as first line therapy in metastatic colorectal cancer: a randomized phasem study显示文摘	Saltz LB Clarke S Diaz-rubio E	2008	J Clin Oncol2008，26，12：	1
7	Outcome of primary tumor in patients with synchronous stage Ⅳ colorectal cancer receiving combination chemotherapy without surgery as initial treatment显示文摘	Poultsides GA Servais EL Saltz LB		0，，20：	1
8	Irinotecan plus fluorouracil/leucovorin(IFL) versus fluorouracil/leucovorin alone(FL) in stage Ⅲ colon cancer(intergroup trial CALGB C89803)显示文摘	Saltz LB Niedzwiecki D Hollis D	2004	Proc Am Soc Clin Oncol2004，，：	1
9	Randomized phase Ⅱ trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinoteean-refractory eolorectal cancer: the BOND-2 study 显示文摘	Saltz LB Lenz HI Kindler HL	2007	J Clin Oncol2007，25，29：	1
10	Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:a randomized phase Ⅲ study显示文摘	Saltz LB Clarke S Diaz-Rubio E	2008	J Clin Oncol2008，26，：	1
11	Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor显示文摘	Saltz LB Meropol NJ Loehrer PJ Sr	2004	J Clin Oncol2004，22，7：	1
12	Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer显示文摘	Saltz LB Cox JV Blank C	2000	N Engl J Med2000，343，13：	1
13	Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor显示文摘	Saltz LB Meropol NJ Loehrer PJ Sr	2004	J Clin Oncol2004，22，7：	1
14	Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard显示文摘	Saltz LB Douillard JY Pirotta N	2001	Oncologist2001，6，1：	1
15	Irinotecan Study Group: irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer显示文摘	Saltz LB Cox JV Blanke C	2000	N Engl J Med2000，343，13：	1
16	Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer显示文摘	SALTZ LB COX JV BLANKE C	2000	N Engl J Med2000，343，13：	1
17	Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer 显示文摘	Saltz LB Cox JV Blanke C	2000	N Engl J Med2000，343，13：	1
18	Phase Ⅱ trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor 显示文摘	SALTZ LB MEROPOL NJ LOEHRER PJ SR	2004	J Clin Oncol2004，22，7：	1
19	Bevacizumab in combination with oxaliplatin-based chemotherapy as firstline therapy in metastatic colorectal cancer: a randomized phase ill study 显示文摘	Saltz LB Clarke S Dfaz-Hubio E	2008	J Clin Oncol2008，26，12：	1
20	Irinotecan plus fluorouracil and leucoverin for metastatic colorectal cancer显示文摘	Saltz LB Cox JV Blanke E	2000	N Engl J Med2000，343，13：	1

返回顶部每页显示：

共11页首页上一页第1页下一页末页 /11 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示